Teriflunomide Attenuates Immunopathological Changes in the Dark Agouti Rat Model of Experimental Autoimmune Encephalomyelitis

Teriflunomide is an oral disease-modifying therapy recently approved in several locations for relapsing-remitting multiple sclerosis. To gain insight into the effects of teriflunomide, immunocyte population changes were measured during progression of experimental autoimmune encephalomyelitis in Dark...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Ringheim, Garth E., Lee, Lan, Laws-Ricker, Lynn, Delohery, Tomas, Liu, Li, Zhang, Donghui, Colletti, Nicholas, Soos, Timothy J., Schroeder, Kendra, Fanelli, Barbara, Tian, Nian, Arendt, Christopher W., Iglesias-Bregna, Deborah, Petty, Margaret, Ji, Zhongqi, Qian, George, Gaur, Rajula, Weinstock, Daniel, Cavallo, Jean, Telsinskas, Juventas, McMonagle-Strucko, Kathleen
Format: Artigo
Idioma:Inglês
Publicat: Frontiers Media S.A. 2013
Matèries:
Neuroscience
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3812666/
https://ncbi.nlm.nih.gov/pubmed/24198809
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fneur.2013.00169
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars